The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Shulgina M.V.

V.A. Almazov National Medical Research Centre — Institute of Medical Education

Mycobacterium tuberculosis drugs resistance mechanisms

Authors:

Shulgina M.V.

More about the authors

Journal: Molecular Genetics, Microbiology and Virology. 2024;42(1): 3‑15

DOI: 10.17116/molgen2024420113

Read: 1675 times

Download PDF (RU)
Contact the author
Table of contents

MYCOBACTERIUM TUBERCULOSIS DRUGS RESISTANCE MECHANISMS
MYCOBACTERIUM TUBERCULOSIS DRUGS RESISTANCE MECHANISMS

To cite this article:

Shulgina MV. Mycobacterium tuberculosis drugs resistance mechanisms. Molecular Genetics, Microbiology and Virology. 2024;42(1):3‑15. (In Russ.)
https://doi.org/10.17116/molgen2024420113

Подписка 2026 Молекулярная генетика, микробиология и вирусология (Molecular Genetics, Microbiology and Virology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
The role of neoadjuvant chemotherapy in the combined treatment of loca­lly adva­nced non-small cell lung cancer and the prerequisites for a personalized approach to it. P.A. Herzen Journal of Onco­logy. 2025;(1):19-25
Abstract:

The review presents analysis of 67 recently published researches, systemic reviews and electronic databases on antituberculosis drugs’ mechanisms of action and mutations associated with or leading to bacterial resistance. The review comprises the data in antibacterials long used ad newly introduced into antituberculosis chemotherapy schemes, as well as new substances considered as perspective antituberculosis drugs.

Keywords:

Mycobacterium tuberculosis
bacterial resistance
antituberculosis drugs mechanisms of action

Authors:

Shulgina M.V.

V.A. Almazov National Medical Research Centre — Institute of Medical Education

Received:

28.01.2024

Accepted:

13.02.2024

Close metadata

References:

  1. Interagency Coordination Group on Antimicrobial Resistance (ICGAR) No time to wait: Securing the future from drug-resistant infections — Report to the Secretary-General of the United Nations, April 2019. . Assessed January 15, 2024. https://www.who.int/antimicrobial-resistance/interagency-coordination-group/final-report/en/
  2. Political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis September, 26, 2018 A/Res/73/L.4. Assessed January 15, 2024. https://press.un.org/en/2023/ga12537.doc.htm
  3. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment: online annexes. World Health Organization 2022. Assessed January 15, 2024. https://www.who.int/publications/i/item/9789240048126
  4. WHO Global tuberculosis report 2022 — Assessed January 15, 2024. https://www.who.int/publications/i/item/9789240061729
  5. Sterlikov SA, Nechaeva OB, Galkin VB, Son IM, Testov VV, Popov SA, et al. Branch and economic indicators of antituberculosis activities 2018—2019. Analytical review of major indicators and statistical data ed. Sterlikov S.A., Cnrihco, M. 2020. (In Russ.). https://mednet.ru/images/materials/CMT/otraslevye_i_ekonomicheskie_2018_2019_final.pdf
  6. Almeida Da Silva P.E., Palomino J.C. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J Antimicrob Chemother. 2011;66(7):1417. https://doi.org/10.1093/jac/dkr173
  7. Cohen T, Sommers B, Murray M. The effect of drug resistance on the fitness of Mycobacterium tuberculosis. Lancet Infect Dis. 2003;3(1):13.  https://doi.org/10.1016/s1473-3099(03)00483-3
  8. Alame Emane AK, Guo X, Takif HE, Liu S. Drug resistance, fitness and compensatory mutations in Mycobacterium tuberculosis. Tuberculosis (Edinb.) 2021;12:102091. https://doi.org/10.1016/j.tube.2021.102091
  9. Müller B, Borrell S, Rose G, Gagneux S. The heterogeneous evolution of multidrug-resistant Mycobacterium tuberculosis. Trends Genet. 2013;29(3):160.  https://doi.org/10.1016/j.tig.2012.11.005
  10. Gillespie SH. Tuberculosis: evolution in millennia and minutes. Biochem Soc Trans. 2007;35(5):1317. https://doi.org/10.1042/BST0351317
  11. Aminov RI. The role of antibiotics and antibiotic resistance in nature. Environ Microbiol. 2009;11(12):2970. https://doi.org/10.1111/j.1462-2920.2009.01972.x
  12. Dutta NK, Karakousis PC. Mechanisms of Action and Resistance of the Antimycobacterial Agents. In: Mayers D., Sobel J., Ouellette M., Kaye K., Marchaim D. (eds). Antimicrob. Drug Resist. Springer International Publishing AG, Cham. 2017;359.  https://doi.org/10.1007/978-3-319-46718-4_25
  13. Shulgina MV, Narvskaya OV, Mokrousov IV, Vasilieva IA. Pathogenic and opportunistic mycobacteria. M.: New-Terra; 2018. (In Russ.). https://www.elibrary.ru/download/elibrary_37413527_15149514.pdf
  14. Berrada ZL, Lin SY, Rodwell TC, Nguyen D, Schecter GF, Pham L, et al. Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex. Diagnostic Microbiol Inf Dis. 2016;85(2):177.  https://doi.org/10.1016/j.diagmicrobio.2016.01.019
  15. Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance. Geneva World Health Organization. 2021. Assessed January 15, 2024. https://www.who.int/publications/i/item/9789240028173
  16. Technical manual for drug susceptibility testing of medicines used in the treatment of tuberculosis (WHO/CDS/TB/2018.24). Geneva: World Health Organization; 2018. Assessed January 15, 2024. https://apps.who.int/iris/bitstream/handle/10665/275469/9789241514842-eng.pdf
  17. Liu L, Jiang F, Chen L, Zhao B, Dong J, Sun L, et al. The impact of combined gene mutations in inhA and ahpC genes on high levels of isoniazid resistance amongst katG non-315 in multidrug-resistant tuberculosis isolates from China. Emerg Microbes Infect. 2018;7(1):183.  https://doi.org/10.1038/s41426-018-0184-0
  18. Kolyva AS, Karakousis PC. Chapter 9: Old and New TB Drugs: Mechanisms of Action and Resistance Understanding Tuberculosis — New Approaches to Fighting Against Drug Resistance. Ed. Cardona P.-J. InTech; 2012;209-232.  https://doi.org/10.5772/30992
  19. Perry JA, Wright GD. Forces shaping the antibiotic resistome. Bioessays. 2014;36(12):1179-1184. https://doi.org/10.1002/bies.201400128
  20. Marrakchi H, Ducasse S, Labesse G, Montrozier H, Margeat E, Emorine L, et al. MabA (FabG1), a Mycobacterium tuberculosis protein involved in the long-chain fatty acid elongation system FAS-II. Microbiology (Reading). 2002;148(Pt 4):951.  https://doi.org/10.1099/00221287-148-4-951
  21. Faïon L, Kamel DK, Rosangela FR, Pintiala C, Cantrelle FX, Moune M, et al. Discovery of the first Mycobacterium tuberculosis MabA (FabG1) inhibitors through a fragment-based screening. Europ J Medicin Chem. 2020;200:112440. https://doi.org/10.1016/j.ejmech.2020.112440
  22. Merker M, Kohl TA, Barilar I, Andres S, Fowler PW, Chryssanthou KA, et al. Phylogenetically informative mutations in genes implicated in antibiotic resistance in Mycobacterium tuberculosis complex. Genome Med. 2020;12(1):27.  https://doi.org/
  23. Drug-resistant tuberculosis: A survival guide for clinicians, 3d edition. (2022 updates). Curry International Tuberculosis Center and California Department of Public Health. 2016;324. Assessed January 15, 2024. https://www.currytbcenter.ucsf.edu/products/view/drug-resistant-tuberculosis-survival-guide-clinicians-3rd-edition
  24. Buchmeier N, Fahey RC. The mshA gene encoding the glycosyltransferase of mycothiol biosynthesis is essential in Mycobacterium tuberculosis Erdman. FEMS Microbiol Lett. 2006;264(1):74.  https://doi.org/10.1111/j.1574-6968.2006.00441.x
  25. Brossier F, Sougakoff W, Bernard C, Petrou M, Adeyema K, Pham A, et al. Molecular analysis of the embCAB Locus and embR gene involved in ethambutol resistance in clinical isolates of Mycobacterium tuberculosis in France. Antimicrob Agents Chemother. 2015;59(8):4800. https://doi.org/10.1111/j.1574-6968.2006.00441.x
  26. Tulyaprawat O, Chaiprasert A, Chongtrakool P, Suwannakarn K, Ngamskulrungroj P. Association of ubiA mutations and high-level of ethambutol resistance among Mycobacterium tuberculosis Thai clinical isolates. Tuberculosis (Edinb). 2019;114:42.  https://doi.org/10.1016/j.tube.2018.11.006
  27. He L, Wang X, Cui P, Jin J, Chen J, Zhang W, Zhang Y. ubiA (Rv3806c) encoding DPPR synthase involved in cell wall synthesis is associated with ethambutol resistance in Mycobacterium tuberculosis. Tuberculosis (Edinb). 2015;95(2):149.  https://doi.org/10.1016/j.tube.2014.12.002
  28. Shi W, Zhang X, Jiang X, Yuan H, Lee JS, Barry CE, 3rd. et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis: a potential mechanism for shortening the duration of tuberculosis chemotherapy. Science (New York, N.Y.). 2011;333(6049):1630. https://doi.org/10.1126/science.1208813
  29. Zhang Y, Wade MM, Scorpio A, Zhang H, Sun Z. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. J Antimicrob Chemother. 2003;52(5):790.  https://doi.org/10.1093/jac/dkg446
  30. Tuberculosis in adults. Clinical Recommendations. 2022. (In Russ.). https://cr.minzdrav.gov.ru/recomend/16_2
  31. Garneau-Tsodikova S, Labby KJ. Mechanisms of Resistance to Aminoglycoside Antibiotics: Overview and Perspectives. Med Chem Comm. 2016;7(1):11.  https://doi.org/10.1039/C5MD00344J
  32. Nguyen L. Antibiotic resistance mechanisms in M. tuberculosis: an update. Arch Toxicol. 2016;90(7):1585. https://doi.org/10.1007/s00204-016-1727-6
  33. Nebenzahl-Guimaraes H, Jacobson KR, Farhat MR, Murray MB. Systematic review of allelic exchange experiments aimed at identifying mutations that confer drug resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2014;69(2):331.  https://doi.org/10.1093/jac/dkt358
  34. Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry. 2014;35(10):1565. https://doi.org/10.1021/bi5000564
  35. Al Matar M, Al Mandeal H, Var I, Kayar B, Köksal F. New drugs for the treatment of Mycobacterium tuberculosis infection. Biomed & Pharmacother. 2017;91:546.  https://doi.org/10.1016/j.biopha.2017.04.105
  36. Maruri F, Sterling TR, Kaiga AW, Blackman A, van der Heijden YF, Mayer C, et al. A systematic review of gyrase mutations associated with fluoroquinolone-resistant Mycobacterium tuberculosis and a proposed gyrase numbering system. J Antimicrob Chemother. 2012;67(4):819.  https://doi.org/10.1093/jac/dkr566
  37. Sirgel FA, Warren RM, Streicher EM, Victor TC, van Helden PD, Böttger EC. gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis. J Antimicrob Chemother. 2012;67(5):1088. https://doi.org/10.1093/jac/dks033
  38. Disratthakit A, Prammananan T, Tribuddharat C, Thaipisuttikul I, Doi N, Leechawengwongs M. et al. Role of gyrB mutations in pre-extensively and extensively drug-resistant tuberculosis in Thai clinical isolates. Antimicrob Agents Chemother. 2016;60:5189. https://doi.org/10.1128/AAC.00539-16
  39. Ajileye A, Alvarez N, Merker M, Walker TM, Akter S, Brown K, et al. Some synonymous and nonsynonymous gyrA mutations in Mycobacterium tuberculosis lead to systematic false-positive fluoroquinolone resistance results with the Hain GenoType MTBDRsl assays. Antimicrob Agents Chemother. 2017;61(4):e02169-16.  https://doi.org/10.1128/AAC.02169-16
  40. Zhang X, Liu L, Zhang Y, Dai G, Huang H, Jin Q. Genetic determinants involved in p-aminosalicylic acid resistance in clinical isolates from tuberculosis patients in northern China from 2006 to 2012. Antimicrob Agents Chemother. 2015;59(2):1320. https://doi.org/10.1128/AAC.03695-14
  41. Zhao F, Wang XD, Erber LN, Luo M, Guo AZ, Yang SS, et al. Binding pocket alterations in dihydrofolate synthase confer resistance to para-aminosalicylic acid in clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2014;58(3):1479. https://doi.org/10.1128/AAC.01775-13
  42. Zheng J, Rubin EJ, Bifani P, Mathys V, Lim V, Au M, et al., para-Aminosalicylic acid is a prodrug targeting dihydrofolate reductase in Mycobacterium tuberculosis. J Biol Chem. 2013;88(32):23447. https://doi.org/10.1074/jbc.M113.475798
  43. Chen J, Zhang S, Cui P, Shi W, Zhang W, Zhang Y. Identification of novel mutations associated with cycloserine resistance in Mycobacterium tuberculosis. J Antimicrob Chemother. 2017;72(12):3272. https://doi.org/10.1093/jac/dkx316
  44. Xu J, Converse PJ, Upton AM, Mdluli K, Fotouhi N, Nuermberger EL. Comparative Efficacy of the Novel Diarylquinoline TBAJ-587 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis. Antimicrob, Agents Chemother. 2021;65(4):e02418-20.  https://doi.org/10.1128/AAC.02418-20
  45. Kadura S, King N, Nakhoul M, Zhu H, Theron G, Köser CU, et al. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs Bedaquiline, Clofazimine, Linezolid, Delamanid and Pretomanid. J Antimicrob Chemother. 2020;75:2031. https://doi.org/10.1093/jac/dkaa136
  46. Almeida D, Ioerger T, Tyagi S, Li SY, Mdluli K, Andries K, et al. Mutations in pepQ Confer Low-Level Resistance to Bedaquiline and Clofazimine in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2016;v.60(8):4590. https://doi.org/10.1128/AAC.00753-16
  47. Almeida DV, Converse PJ, Nuermberger EL. Mutations in Rv0678 Reduce Susceptibility of Mycobacterium tuberculosis to the DprE1 Inhibitor TBA-7371. Antimicrob Agents Chemother. 2023;67(3):e0005223. https://doi.org/10.1128/aac.00052-23
  48. Mokrousov I, Akhmedova G, Molchanov V, Fundovnaya E, Kozlova E, Ostankova Y, et al. Frequent acquisition of Bedaquiline resistance by epidemic extensively drug-resistant Mycobacterium tuberculosis strains in Russia during long-term treatment. Clin Microbiol Infect. 2021;27:478.  https://doi.org/10.1016/j.cmi.2020.08.030
  49. Xu J, Wang B, Hu M, Huo F, Guo S, Jing W, et al. Primary Clofazimine and Bedaquiline resistance among isolates from patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother. 2017;61(6):e00239-17.  https://doi.org/10.1128/AAC.00239-17
  50. Zheng H, He W, Jiao W, Xia H, Sun L, Wand S, et al. Molecular characterization of multidrug-resistant tuberculosis against Levofloxacin, Moxifloxacin, Bedaquiline, Linezolid, Clofazimine, and Delamanid in Southwest of China. BMC Infect Dis. 2021;21:330.  https://doi.org/10.1186/s12879-021-06024-8
  51. Cellitti SE, Shaffer J, Jones DH, Mukherjee T, Gurumurthy M, Bursulaya B, et al. Structure of Ddn, the deazaflavin-dependent nitroreductase from Mycobacterium tuberculosis involved in bioreductive activation of PA-824. Structure. 2012;20(1):101.  https://doi.org/10.1016/j.str.2011.11.001
  52. Wang F, Yuan Q, Chen F, Pang J, Pan C, Xu F, Chen Y. Fundamental Mechanisms of the Cell Death Caused by Nitrosative Stress. Front Cell Dev Biol. 2021;9:742483. https://doi.org/10.3389/fcell.2021.742483
  53. Jirapanjawat T, Ney B, Taylor MC, Warden AC, Afroze S, Russell RJ, et al. The Redox Cofactor F420 Protects Mycobacteria from Diverse Antimicrobial Compounds and Mediates a Reductive Detoxification System. Appl Environ Microbiol. 2016;82(23):6810. https://doi.org/10.1128/AEM.02500-16
  54. Rifat D, Li SY, Ioerger T, Shah K, Lanoix JP, Lee J, et al. Mutations in fbiD (Rv2983) as a novel determinant of resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2020;65(1):e01948-20.  https://doi.org/10.1128/AAC.01948-20
  55. Battaglia S, Spitaleri A, Cabibbe AM, Meehan CJ, Utpatel C, Ismail N, et al. Characterization of genomic variants associated with resistance to Bedaquiline and Delamanid in naive Mycobacterium tuberculosis clinical strains. J Clin Microbiol. 2020;58:e01304-20.  https://doi.org/10.1128/JCM.01304-20
  56. Haver HL, Chua A, Ghode P, Lakshminarayana SB, Singhal A, Mathema B, et al. Mutations in genes for the F420 biosynthetic pathway and a nitroreductase enzyme are the primary resistance determinants in spontaneous in vitro-selected PA-824-resistant mutants of Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015;59:5316. https://doi.org/10.1128/AAC.00308-15
  57. Rupasinghe P, Reenaers R, Vereecken J, Mulders W, Cogneau S, Merker M, et al. Refined understanding of the impact of the Mycobacterium tuberculosis complex diversity on the intrinsic susceptibility to pretomanid. Microbiol Spectr. 2024;e00070-24.  https://doi.org/10.1128/spectrum.00070-24
  58. Zhang S, Chen J, Cui P, Shi W, Shi X, Niu H, et al. Mycobacterium tuberculosis mutations associated with reduced susceptibility to Linezolid. Antimicrob Agents Chemother. 2016;60(4):2542. https://doi.org/10.1128/AAC.02941-15
  59. World Health Organization. Status of the pipeline for new TB products//-2022. Assessed January 15, 2024. https://www.who.int/observatories/global-observatory-on-health-research-and-development/analyses-and-syntheses/tuberculosis/analysis-of-tb-r-d-pipeline
  60. Stop TB Partnership Working group on new drugs. Assessed January 15, 2024. www.newtbdrugs.org
  61. Pidot SJ, Rizzacasa MA. The Nargenicin Family of oxa-bridged macrolide antibiotics. Chem Europe. 2020;26(13):2780. https://doi.org/10.1002/chem.201904053
  62. Dartois VA, Rubin EJ. Anti-tuberculosis treatment strategies and drug development: challenges and priorities. Nat Rev Microbiol. 2022;20:685.  https://doi.org/10.1038/s41579-022-00731-y
  63. Black TA, Ulrike K, Buchwald UK. The pipeline of new molecules and regimens against drug-resistant tuberculosis. J Clin Tuberc Other Mycobact Dis. 2021;25:100285. https://doi.org/10.1016/j.jctube.2021.100285
  64. Bonsa Z, Tadesse M, Balay G, Kebede W, Abebe G. Discordance between genotypic and phenotypic methods for the detection of rifampicin and isoniazid resistant Mycobacterium tuberculosis and the correlation with patient treatment outcomes J Clin Tuberculosis and Other Mycobact Dis. 2024;34:100410. https://doi.org/10.1016/j.jctube.2023.100410
  65. Rieder HL, Van Deun A. Rationale for high-dose isoniazid in the treatment of multidrug-resistant tuberculosis. Int J Tuber Lung Dis. 2017;21(1):123.  https://doi.org/10.5588/ijtld.16.0619
  66. Valafar SJ. Systematic Review of Mutations Associated with Isoniazid Resistance Points to Continuing Evolution and Subsequent Evasion of Molecular Detection, and Potential for Emergence of Multidrug Resistance in Clinical Strains of Mycobacterium tuberculosis. Antimicrob Agents and Chemoth. 2021;65(3):e02091. https://doi.org/e02091-20
  67. Domínguez J, Boeree MJ, Cambau E, Chesov D, Conradie F, Cox V, et al. TBnet and RESIST-TB networks. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a 2023 TBnet/RESIST-TB consensus statement. Lancet Infect Dis. 2023;23(4):e122. https://doi.org/10.1016/S1473-3099(22)00875-1
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.